Reach the HCPs whose patients are ready now.
Volume tells you who prescribes today. It says far less about who is about to change. Patient-journey targeting finds the physicians whose patients are approaching a treatment decision, straight from the claims.
Rank your target list by opportunity, not history.
Most HCP targeting ranks physicians on prescription volume and willingness to switch. Both describe what already happened. Patient-journey targeting adds the signal that predicts near-term change: how much of each physician’s panel is approaching a treatment decision, read from diagnosis, testing, therapy gaps, switching, and progression in the claims. It sits on top of the target list you already build, and reweights it by live opportunity.
Find readiness, not just volume
Surface the physicians with patients ready to start or switch now, including those a volume-ranked plan tends to miss.
Concentrate the budget
Point limited outreach at the pockets of real, near-term opportunity rather than spreading it across already-maxed writers.
Works across therapy areas
Oncology, respiratory, cardiometabolic, any therapy with a defined treatment pathway. The engine is the same; the signals adapt.
See the approach in a published case study.
Solli, the pharma-media knowledge platform, published a case study on patient-journey based HCP targeting and the results it produced for an oncology brand defending share.
Hosted independently on Solli.
From claims signal to a sharper list.
Journey signals
Diagnosis, testing, therapy gaps, switching and progression across the patient panel.
Readiness score
Estimated share of each physician’s patients approaching a decision in 30, 90 or 180 days.
Reweighted list
Your existing target list resorted by live opportunity, ready for activation.
Measured lift
A matched control holds the result to incremental lift, not post-campaign movement.
See how it would reorder your next brand’s list.
Bring your indication and target universe. We will show you what patient-journey targeting surfaces that volume ranking misses.
Talk to the MedFuse team